NVCT logo

NVCT Nuvectis Pharma, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$19.39
-0.45 (-2.27%)

Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candida…

Market Cap: $666.80Mwww.nuvectis.com

Price

No data yet.

Social Signal Score

50
5d
60
1 mentions
—
30d
46
5 mentions
—
60d
47
6 mentions
—
90d
47
7 mentions
—
news: 7

Analyst Ratings

3 analysts
Buyconsensus
Strong Buy 0Buy 3Hold 0Sell 0Strong Sell 0
Avg price target$37.33+92.5%
Low $33Median $39High $40
Current Consensus

Revenue

$0.00
$0.00
Mar 2021Sep 2026

Analyst Estimates

FY2025
$-1.32
$-1.39–$-1.26
3 analysts
FY2026
$-2.03
$-2.05–$-2.01
5 analysts
FY2027
$-1.70
$-2.34–$-1.26
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Ron Bentsur
Sector
Healthcare
Industry
Biotechnology
Employees
19
Beta
-0.24
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
26.62
www.nuvectis.com